Researchers at University Hospital Southampton NHS Foundation Trust (UHS) are leading the first study into the long-term benefits and safety of using eplerenone — a drug used to treat heart failure — to treat central serous chorio-retinopathy (CSCR).
The £1 million project will reportedly involve 104 patients across 20 sites in the U.K., and participants will receive either the medication or an identical placebo tablet for up to 12 months. According to researchers, recently a small number of patients responded to treatment with eplerenone. However, information on the long-term benefit and safety is lacking, so this trial will reportedly help establish the first scientifically proven therapy for CSCR.
Click here to read the full press release.
Like what you read? Follow OphthalmologyWeb to keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.
Source: University Hospital Southampton NHS Foundation Trust